Neonatal jaundice pathophysiology: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Neonatal jaundice}} | {{Neonatal jaundice}} | ||
{{CMG}} {{AE}} | {{CMG}}; {{AE}} {{AEL}} | ||
{{ | |||
==Overview== | ==Overview== |
Revision as of 20:19, 2 January 2018
Neonatal jaundice Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Neonatal jaundice pathophysiology On the Web |
American Roentgen Ray Society Images of Neonatal jaundice pathophysiology |
Risk calculators and risk factors for Neonatal jaundice pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
Pathophysiology
In neonates, benign jaundice tends to develop because of two factors - the breakdown of fetal hemoglobin as it is replaced withadult hemoglobin and the relatively immature hepatic metabolic pathways which are unable to conjugate and so excrete bilirubin as fast as an adult. This causes an accumulation of bilirubin in the body (hyperbilirubinemia), leading to the symptoms of jaundice.
Severe neonatal jaundice may indicate the presence of other conditions contributing to the elevated bilirubin levels, of which there are a large variety of possibilities (see below). These should be detected or excluded as part of the differential diagnosis to prevent the development of complications. They can be grouped into the following categories: